Naropin Injection, Solution
Product Images NDC 63323-287

Product Visual Gallery

This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Naropin (NDC 63323-287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Nar01 0005 01

Chemical structure of Ropivacaine hydrochloride monohydrate, the active ingredient in Naropin injection solution. The image shows the molecular structure along with the molecular formula C17H26N2O•HCl•H2O and molecular weight 328.89.*

FDA Label Image

Nar01 0005 02

FDA Label Image

Nar01 0005 03

Naropin 0.2% (ropivacaine hydrochloride injection, USP) 20 mg per 10 mL (2 mg per mL) solution in a 10 mL single dose vial. Label indicates use for infiltration, nerve block, and epidural administration only, not for intravenous use. Manufactured by Fresenius Kabi USA, LLC with storage instructions at 20° to 25°C.*

FDA Label Image

Nar01 0005 04

Label for Naropin (ropivacaine HCl Injection, USP) 0.2% solution containing 20 mg per 10 mL (2 mg per mL), in 10 mL single dose vials. Indicated for infiltration, nerve block, and epidural administration only, not for intravenous use. Manufactured by Fresenius Kabi USA, LLC, with storage and usage instructions included.*

FDA Label Image

Nar01 0005 05

Naropin 0.2% (ropivacaine HCl Injection, USP) 40 mg per 20 mL (2 mg per mL) solution in a 20 mL single dose vial. Label includes usage instructions for infiltration, nerve block, and epidural administration only; not for intravenous use. Distributed by Fresenius Kabi USA, LLC with storage information at 20° to 25°C.*

FDA Label Image

Nar01 0005 06

Naropin 0.2% (ropivacaine HCl injection) solution label for 40 mg per 20 mL (2 mg/mL) in single dose vials. Intended for infiltration, nerve block, and epidural administration only, not for intravenous use. Contains no preservatives. Manufactured by Fresenius Kabi USA, LLC. Storage and usage instructions included on the label.*

FDA Label Image

Nar01 0005 07

Naropin 0.5% (Ropivacaine HCl Injection, USP) 5 mg/mL solution, 20 mL single dose vial. The label states 100 mg per 20 mL and indicates usage for infiltration, nerve block, and epidural administration only, not for intravenous use. Labeled by Fresenius Kabi USA, LLC, with storage instructions at 20° to 25°C (68° to 77°F).*

FDA Label Image

Nar01 0005 08

Label for Naropin 0.5% (ropivacaine HCl injection, USP) solution, 100 mg per 20 mL (5 mg per mL) in a 20 mL single dose vial. The label states use for infiltration, nerve block, and epidural administration only, not for intravenous use. It includes ingredient details, storage instructions, and a Fresenius Kabi USA, LLC logo and address.*

FDA Label Image

Nar01 0005 09

Naropin 0.5% (ropivacaine HCl injection, USP) 5 mg/mL solution in a 30 mL single dose vial. The label includes usage restrictions for infiltration, nerve block, and epidural administration only, not for intravenous use. Manufactured by Fresenius Kabi USA, LLC, with storage instructions at 20° to 25°C (68° to 77°F).*

FDA Label Image

Nar01 0005 10

Naropin 0.5% (ropivacaine HCl injection, USP) 150 mg per 30 mL (5 mg per mL) injection solution labeling. The label displays product strength, dosage form, and single-use vial packaging with five 30 mL sterile, presterilized vials per pack. It includes directions for controlled room temperature storage and specifies use for infiltration, nerve block, and epidural administration only. The labeler is Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 11

Naropin 0.5% (ropivacaine HCl Injection, USP) solution, 150 mg per 30 mL (5 mg per mL) in a 30 mL single dose vial. Label includes storage instructions at 20° to 25°C, administration restrictions for infiltration, nerve block, and epidural use only, and states it is not for intravenous administration. Manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 12

Naropin 0.5% (ropivacaine HCl injection, USP) 150 mg per 30 mL (5 mg per mL) in 30 mL single dose vials for infiltration, nerve block, and epidural administration. Label shows ingredients, usage restrictions, storage instructions, no preservatives, and is produced by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 13

Naropin 0.75% (ropivacaine HCl Injection, USP) 150 mg per 20 mL (7.5 mg per mL) injection solution label. This single dose vial contains 20 mL and is indicated for nerve block and epidural administration only, not for intravenous use. Labeler is Fresenius Kabi USA, LLC, Lake Zurich, IL, with storage instructions for controlled room temperature (20° to 25°C).*

FDA Label Image

Nar01 0005 14

Naropin 0.75% (ropivacaine HCl injection USP) 7.5 mg/mL, 150 mg per 20 mL vial. Label states it is for nerve block and epidural administration only, not for intravenous use. The package contains twenty-five 20 mL single dose vials. Manufactured by Fresenius Kabi USA, LLC in Lake Zurich, IL.*

FDA Label Image

Nar01 0005 15

Label for Naropin (ropivacaine hydrochloride) Injection, USP, 1% solution (10 mg/mL), provided as 100 mg per 10 mL in a single-dose vial. The label states it is for epidural administration only and not for intravenous use. It includes storage instructions at 20° to 25°C and identifies Fresenius Kabi USA, LLC as the labeler with their contact information and website.*

FDA Label Image

Nar01 0005 16

Label for Naropin (ropivacaine HCl Injection, USP) 10 mg/mL solution for injection in 10 mL single-dose vials. The label states the product is for epidural administration only, not intravenous. It includes ingredients, storage instructions, and manufacturer Fresenius Kabi USA, LLC, with NDC 63323-288.*

FDA Label Image

Nar01 0005 17

Naropin 1% (ropivacaine hydrochloride) Injection, USP 200 mg per 20 mL (10 mg/mL) in a 20 mL single-dose vial. The label specifies use for epidural administration only and states it is not for intravenous administration. Manufactured by Fresenius Kabi USA, LLC, with storage instructions at 20° to 25°C (68° to 77°F).*

FDA Label Image

Nar01 0005 18

Naropin 1% (ropivacaine HCl Injection, USP) label for 200 mg per 20 mL (10 mg per mL) solution. The label indicates it is for epidural administration only, not for intravenous use. Packaging is for twenty-five 20 mL single dose vials. Labeler is Fresenius Kabi USA, LLC. Contains prescribing and storage instructions, ingredient details, and a barcode.*

FDA Label Image

Nar01 0005 19

Naropin 0.2% (ropivacaine HCl Injection, USP) solution in a 200 mL vial. Contains 400 mg per 200 mL (2 mg per mL) for infiltration, nerve block, and epidural administration only. Not for intravenous use. Label shows storage instructions, preservative information, and manufacturer Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 20

Naropin 0.2% (Ropivacaine HCl injection, USP) 200 mg per 100 mL (2 mg per mL) solution for injection. The label indicates the product is for infiltration, nerve block, and epidural administration only, not for intravenous use. The package contains 100 mL and is labeled for single dose use, with instructions to discard unused portions. Manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 21

Naropin 0.5% (Ropivacaine HCl injection, USP) 500 mg per 100 mL (5 mg/mL) solution label for injection. The label indicates use for infiltration, nerve block, and epidural administration only, not for intravenous use. It states single dose only and storage instructions at 20° to 25°C. The label includes barcodes, manufacturer Fresenius Kabi USA, LLC, and lot/expiration placeholders.*

FDA Label Image

Nar01 0005 22

Naropin 0.5% (Ropivacaine HCl Injection, USP) 1,000 mg per 200 mL (5 mg per mL) injection solution. The label indicates 200 mL vial size with a concentration of 5 mg/mL. It is labeled for infiltration, nerve block, and epidural administration only, not for intravenous use. Contains no preservatives. Manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 23

Naropin 0.2% (ropivacaine hydrochloride) injection, USP, 20 mg per 10 mL (2 mg per mL) in a 10 mL ampule. Label indicates it is not for inhalation and is Rx only. Manufactured for Fresenius Kabi USA, LLC, Lake Zurich, IL, made in Norway. Includes barcode and NDC 63323-285-01.*

FDA Label Image

Nar01 0005 24

Naropin 0.2% (ropivacaine HCl injection) sterile 10 mL plastic ampule label. Contains 20 mg per 10 mL (2 mg per mL) ropivacaine hydrochloride injection. Label states use for infiltration, nerve block, and epidural administration only; not for intravenous administration or inhalation. Manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 25

Naropin 0.2% (ropivacaine HCl injection, USP) label for Injection, Solution. The label indicates a concentration of 20 mg per 10 mL (2 mg per mL), intended for infiltration, nerve block, and epidural administration only, not for intravenous administration or inhalation. The packaging contains five presterilized 10 mL plastic ampule units and is labeled with the Fresenius Kabi logo as the manufacturer.*

FDA Label Image

Nar01 0005 26

Naropin 0.2% (ropivacaine HCl Injection, USP) 20 mL ampule label showing 40 mg per 20 mL (2 mg per mL) strength. The label indicates it is not for inhalation, prescription only, manufactured for Fresenius Kabi USA, LLC in Lake Zurich, IL, and made in Norway. Barcode and QR code are present.*

FDA Label Image

Nar01 0005 27

Naropin 0.2% (ropivacaine HCl injection) solution in a 20 mL plastic ampule, containing 40 mg per 20 mL (2 mg/mL). The label indicates the product is for infiltration, nerve block, and epidural administration only and is not for intravenous or inhalation use. The ampule is sterile and presterilized, packaged by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 28

Naropin 0.2% (ropivacaine HCl Injection, USP) 40 mg per 20 mL (2 mg/mL) injection solution packaging label. The label specifies it is for infiltration, nerve block, and epidural administration only, not for intravenous or inhalation use. The product contains five presterilized 20 mL plastic ampule units. Manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 29

Naropin 7.5 mg/mL (0.75%) ropivacaine hydrochloride injection, USP, 20 mL ampule. Label indicates 150 mg per 20 mL. The product is for epidural and perineural use and is not for inhalation. Manufactured by Fresenius Kabi USA, LLC, Lake Zurich, IL, made in Norway.*

FDA Label Image

Nar01 0005 30

Naropin 0.75% (Ropivacaine HCl Injection, 7.5 mg/mL) sterile 20 mL plastic ampule label. Contains 150 mg per 20 mL, for nerve block and epidural administration only, not for intravenous use. Labeled as Rx only by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 31

Naropin 0.75% (ropivacaine HCl injection, USP) 150 mg per 20 mL (7.5 mg per mL) sterile injection solution for nerve block and epidural administration only, not for inhalation. The label shows a Sterile-Pak containing five presterilized 20 mL plastic ampule units. Manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 32

Label for Naropin (ropivacaine HCl Injection USP) 0.5% (5 mg/mL) in a 20 mL ampule, containing 100 mg per 20 mL. The label states "NOT FOR INHALATION," indicates prescription use only, and notes the manufacturer as Fresenius Kabi, Lake Zurich, IL. The product is made in Norway.*

FDA Label Image

Nar01 0005 33

Naropin 0.5% (ropivacaine HCl injection, USP) 100 mg per 20 mL (5 mg per mL) sterile plastic ampule label. The label indicates use for infiltration, nerve block, and epidural administration only, not for intravenous or inhalation use. The product contains one presterilized 20 mL plastic ampule and is manufactured by Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 34

Naropin 0.5% (ropivacaine HCl injection, USP) 100 mg per 20 mL (5 mg per mL) injection solution for infiltration, nerve block, and epidural administration. The carton contains five presterilized 20 mL plastic ampoule units. Labeler: Fresenius Kabi USA, LLC. Not for inhalation. Rx only.*

FDA Label Image

Nar01 0005 35

Label for Naropin (ropivacaine HCl Injection, USP) 1% solution, containing 100 mg per 10 mL (10 mg/mL). It is a 10 mL ampule for injection, indicated as not for inhalation and available by prescription only. Manufactured for Fresenius Kabi USA, LLC, based in Lake Zurich, Illinois, with the product made in Norway.*

FDA Label Image

Nar01 0005 36

Naropin 1% (Ropivacaine HCl Injection, USP) sterile solution in a 10 mL plastic ampule. Each 10 mL contains 100 mg (10 mg/mL) of the active ingredient. Label states the product is for epidural administration only and not for intravenous administration or inhalation. Manufactured for Fresenius Kabi USA, LLC. Includes storage instructions and barcode.*

FDA Label Image

Nar01 0005 37

Packaging label for Naropin 1% (ropivacaine HCl injection, USP) 100 mg per 10 mL (10 mg per mL) solution for injection. The label states it is for epidural administration only, not for intravenous administration, and not for inhalation. It is a Sterile-Pak containing five presterilized 10 mL plastic ampule units. The labeler is Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 38

Naropin 1% (Ropivacaine HCl Injection, USP) label for 200 mg per 20 mL (10 mg per mL) solution in a 20 mL ampule. The label states it is not for inhalation and is Rx only. Manufactured for Fresenius Kabi USA, LLC, Lake Zurich, IL, made in Norway.*

FDA Label Image

Nar01 0005 39

Naropin 1% (ropivacaine HCl injection USP) 200 mg per 20 mL (10 mg per mL) sterile premixed plastic ampule label. The label states it is for epidural administration only and not for intravenous use. The ampule contains 20 mL of solution, is sterile in unopened packaging, and should be stored at 20° to 25°C. It includes manufacturer details for Fresenius Kabi USA, LLC.*

FDA Label Image

Nar01 0005 40

Naropin 1% (ropivacaine HCl injection, USP) 200 mg per 20 mL (10 mg per mL) injection solution carton. Contains five presterilized 20 mL plastic ampule units. Labeled for epidural administration only, not for intravenous use or inhalation. Manufactured by Fresenius Kabi USA, LLC. Includes instructions for use and storage information.*

FDA Label Image

Nar01 0005 41

Naropin 0.2% (Ropivacaine HCl Injection, USP) 2 mg/mL injection solution, 100 mL vial, labeled for infiltration and epidural administration. The label shows active ingredient concentration, storage instructions, single dose use, manufacturer Fresenius Kabi USA, LLC, and indicates the product is made in Norway with NDC 63323-285.*

FDA Label Image

Nar01 0005 42

Label for Naropin (ropivacaine HCl Injection, USP) 2 mg/mL (200 mg/100 mL) solution for injection. The label shows a 100 mL vial in a 24-count package, listing Fresenius Kabi USA, LLC as the manufacturer. Storage instructions specify 20° to 25°C (68° to 77°F). The label includes NDC 63323-285-61, barcode, lot number, and expiration date placeholders.*

FDA Label Image

Nar01 0005 43

Naropin 0.2% (ropivacaine HCl injection, USP) solution, 2 mg/mL strength, 200 mL vial. Label indicates use for infiltration and epidural administration only, single-dose, preservative-free. Contains Ropivacaine HCl and sodium chloride with pH adjusted between 4.0 and 6.0. Manufactured by Fresenius Kabi USA, LLC in Norway. Includes storage instructions and barcode.*

FDA Label Image

Nar01 0005 44

Naropin 2 mg/mL (ropivacaine HCl injection, USP) solution in a 200 mL vial with 24 count. The label includes storage instructions (20° to 25°C), manufacturer details Fresenius Kabi USA, LLC, and indicates the product is made in Norway. Barcodes, lot number, and expiration date fields are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.